Zobrazeno 1 - 10
of 51
pro vyhledávání: '"Metin, Seker"'
Autor:
Nalan A Babacan, Hatice Reyhan Egilmez, Birsen Yücel, Parlak Ilknur, Mehmet Metin Seker, Turgut Kaçan, Aykut Bahçeci, Sener Cihan, Bülent Akinci, Berna Eriten, Saadettin Kiliçkap
Publikováno v:
The Saudi Journal of Gastroenterology, Vol 22, Iss 1, Pp 25-29 (2016)
Background/Aims: This study aimed to examine whether UHRF-1 and p53 overexpression is a prognostic marker for gastric cancer. Patients and Methods: Sixty-four patients with gastric cancer (study group) and 23 patients with gastritis (control group) w
Externí odkaz:
https://doaj.org/article/8e57663b45ca467b843989c38a4daf9e
Autor:
Ahmet Bilici, Sinan Koca, Mustafa Karaagac, Sabin Goktas Aydin, Emrah Eraslan, Muhammed Ali Kaplan, Birol Ocak, Sema Sezgin Goksu, Semra Paydas, Fahri Akgul, Sumeyye Derin, Yakup Ergun, Emre Yekeduz, Cihan Erol, Deniz Tataroglu Ozyukseler, Atike Gokcen Demiray, Mustafa Karaca, Zeynep Gulsum Guc, Serkan Menekse, Havva Yesil Cinkir, Ozge Gumusay, Abdullah Sakin, Ozlem Ozkul, Hacer Demir, Dilek Erdem, Mehmet Besiroglu, Olcun Umit Unal, Ramazan Acar, Lokman Koral, Suleyman Sahin, Teoman Sakalar, Aykut Bahceci, Ahmet Ozveren, Ulug Mutlu Gunaydin, Mehmet Metin Seker, Veli Sunar, Pinar Dal, Mehmet Artac, Serdar Turhal
Aim: Description of patient characteristics, effectiveness and safety in Turkish patients treated with pazopanib for metastatic soft tissue sarcoma (STS). Patients and methods: This multicenter study is based on retrospective review of hospital medic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e475dde06decc907f161d14d4d0f2ae4
https://avesis.deu.edu.tr/publication/details/c895112d-5502-4614-a59b-a819d23aebc3/oai
https://avesis.deu.edu.tr/publication/details/c895112d-5502-4614-a59b-a819d23aebc3/oai
Autor:
Mehmet Metin Seker, Ali Ugur Uslu, Hatice Ozer, Ayse Seker, Turgut Kacan, Nalan Babacan, Handan Aker, Sahande Elagoz
Publikováno v:
Menopause Review, Vol 13, Iss 6, Pp 356-358 (2014)
Endocervical stromal sarcoma (ECSS) is a very rare uterine sarcoma. The most common presentation is pelvic mass and vaginal bleeding. The mainstay of treatment is surgery. There is no consensus on the adjuvant treatment. Relapses are usually in the p
Externí odkaz:
https://doaj.org/article/9a7b985270c241c6837b3d596d90973f
Publikováno v:
The Saudi Journal of Gastroenterology, Vol 19, Iss 6, Pp 258-261 (2013)
Background/Aim: Gastric cancer (GC) is considered to be a disease of elderly patients. It has been suggested that GC in young adults has more aggressive clinical and pathologic features than in adults. In this study we aimed to evaluate clinical and
Externí odkaz:
https://doaj.org/article/b74d2cc6fc6c45a1ab30b99123d67736
Autor:
Sukru Ozaydin, Caglayan Geredeli, Mehmet Fatih Can, Mahmut Gumus, Özlem Nuray Sever, Abdullah Sakin, Turkan Ozturk Topcu, Abdurrahman Isikdogan, Mehmet Metin Seker, Keziban Nur Pilanci, Muhammet Ali Kaplan, Faysal Dane, Ulku Yalcintas Arslan, Timucin Cil, Nuriye Ozdemir, Mustafa Karaagac, Mehmet Bilici, Zeynep Oruc Seker, Halis Yerlikaya, Mukremin Uysal, Dogan Koca, Asude Aksoy
Publikováno v:
Oncology Research and Treatment. 42:516-522
Background: Colorectal cancer (CRC) is a rare disease amongst children and adolescents. Previous studies have reported a number of differences between children/adolescents, young adults, and adult patients with CRC. However, none of these studies com
Publikováno v:
Geburtshilfe und Frauenheilkunde. 77:66-72
WOS: 000393553000012
PubMed ID: 28190891
Introduction Mammalian target of rapamycin is a pathway to block apoptosis. Recent studies showed that the activity of mammalian target of rapamycin pathway increases in endometriotic lesions. Aim of
PubMed ID: 28190891
Introduction Mammalian target of rapamycin is a pathway to block apoptosis. Recent studies showed that the activity of mammalian target of rapamycin pathway increases in endometriotic lesions. Aim of
Autor:
Yusuf Gunaydin, Alper Sevinc, Mahmut Gumus, Hatice Odabas, Ibrahim Vedat Bayoglu, Esma Turkmen, Nurten Kandemir, Sener Cihan, Z. Urakci, Ahmet Bilici, Turkan Ozturk, Nedim Turan, Fatih Selcukbiricik, Umut Demirci, Mehmet Metin Seker, Bala Basak Oven Ustaalioglu
Publikováno v:
World Journal of Urology. 35:1103-1110
WOS: 000404154000013
PubMed ID: 27812752
Background Currently, it is accepted that risk assessment of clinical stage I (CS I) nonseminomatous germ cell tumors (NSGCT) patient is mainly dependent on the presence of lymphovascular invasion (L
PubMed ID: 27812752
Background Currently, it is accepted that risk assessment of clinical stage I (CS I) nonseminomatous germ cell tumors (NSGCT) patient is mainly dependent on the presence of lymphovascular invasion (L
Autor:
Turgut Kacan, Selen Baloglu Kacan, Özlem Bozoklu Akkar, Savas Karakus, Ali Cetin, Hatice Özer, Caglar Yildiz, Metin Seker
Publikováno v:
European Journal of Obstetrics & Gynecology and Reproductive Biology. 197:159-163
WOS: 000371187300030
PubMed ID: 26773307
Objective: Currently, medical and surgical treatment options for endometriosis are limited due to suboptimal efficacy, and also safety and tolerance issues. Long-term use of gonadotrophin-releasing h
PubMed ID: 26773307
Objective: Currently, medical and surgical treatment options for endometriosis are limited due to suboptimal efficacy, and also safety and tolerance issues. Long-term use of gonadotrophin-releasing h
43rd ESMO Congress (ESMO) -- OCT 19-23, 2018 -- Munich, GERMANY
WOS: 000459277301273
…
European Soc Med Oncol, Japanese Soc Med Oncol
WOS: 000459277301273
…
European Soc Med Oncol, Japanese Soc Med Oncol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::021715afdc6b019d838ff06443f393a7
https://hdl.handle.net/20.500.12418/6121
https://hdl.handle.net/20.500.12418/6121
Autor:
Ersin, Ozaslan, Ulaş Serkan, Topaloglu, Mevlude, Inanc, Umut, Gokmen Erdem, Hacer, Demir, Erkan, Arpaci, Mehmet, Metin Seker, Mustafa, Karaagac, Melih, Kiziltepe, Baki, Eker, Metin, Ozkan
Publikováno v:
Journal of B.U.ON. : official journal of the Balkan Union of Oncology. 22(4)
To evaluate the efficacy and adverse events with cetuximab plus FOLFOX administered as second- and third-line therapy in metastatic colorectal cancer (mCRC) patients.IPatients were administered cetuximab plus FOLFOX as second- and third-line therapy